Part of cannabis and investing
Cannabis company Hexo Corp. outlined its plans to enter eight U.S. states with cannabidiol (CBD) products in 2020 as it reported third-quarter earnings that fell short of expectations, sending its stock lower.
Hexo chief executive Sebastien St-Louis would not say which states the cannabis producer was prioritizing, but the company expects to enter the U.S. market through a joint venture with Molson Coors Brewing Co.
He added that it plans to launch a suite of products and is in varying levels of discussion with roughly 60 Fortune 500 companies for potential partnerships.
“We think we can enter with our Fortune 500 partners. … We think we can lever their existing distribution and go through non-marijuana channels,” he said on a conference call on Thursday.
Cannabis is legal for medical and recreational use in several U.S. states, but remains illegal at the federal level south of the border. However, the passage of a U.S. law late last year has allowed for the growing of hemp for the purposes of extracting CBD.
Hexo already has a Canadian joint venture with Molson Coors for a portfolio of cannabis-infused beverages, called Truss. Mr. St-Louis said the company plans to enter the U.S. beverage market with a similar type of partnership with Molson.
Gatineau-based Hexo’s U.S. plans came as it reported financial results for its third quarter.
During the three months ended April 30, Hexo saw net revenues of $13-million, up from $1.24-million during the same period a year earlier before the legalization of recreational cannabis in Canada last October.
However, its latest quarterly revenues fell short of the $14-million expected by analysts, according to Thomson Reuters Eikon.
Hexo’s quarterly net loss deepened to $7.75-million, from a $1.97-million loss a year earlier, as operating expenses jumped to $24.1-million from $5.3-million during the same period in 2018.
The company’s stock on the Toronto Stock Exchange on Thursday slipped as low as $7.78, down 8.8 per cent from $8.53 on Wednesday.
RBC Capital Markets analyst Douglas Miehm said Hexo’s results were “a little light” relative to estimates.
“Though, we note that the variance (at least compared to RBCCM) was driven by the company’s medical business, with the more important adult-use segment tracking in line with expectations,” he said in a note to clients.
Hexo said Thursday that it still expects to ramp its net revenue to $400-million by its 2020 financial year.
However, there are two factors that could put that $400-million target at risk, Mr. St-Louis said. Hexo’s Belleville, Ont., facility must be operational by the fall, but the company expects it will be ready in time, he told analysts.
As well, the legalization of edibles and other next-generation cannabis products are expected to be legalized in the coming months, but long delays would push the timing back, Mr. St-Louis said.
Health Canada has completed its consultation on the draft version of the regulations, but has yet to release the final rules.
“It would be prudent to expect a delay, potentially into December,” Mr. St-Louis said on the conference call. “But if it’s further delayed, that could put upwards of $100-million of that $400-million at risk. … As we’re planning advanced products to be about 25 per cent.”
Hexo’s $400-million revenue guidance does not include its U.S. plans, he noted.
The cannabis company says it has secured a supply of 60,000 kilograms of hemp for extraction of CBD, the compound which can be derived from both cannabis and hemp, in preparation for the coming edibles market and its U.S. launch in 2020. It has also entered into a supply agreement for 200,000 kg of hemp to be supplied during its 2020 financial year.
Available now: Cannabis Professional, the authoritative news service tailored specifically for professionals in the rapidly evolving cannabis industry. Subscribe now.